Prostate-specific antigen (PSA) is routinely used as a biomarker for the diagnosis, prognosis, and monitoring of disease progression in prostate cancer, although the benefit of PSA testing remains controversial [2]. This evidence concerns the gene KLK3 and Familial prostate cancer.